Biotech’s recognition on Wall Street continues to emanate outrageous windfalls for most of the industry’s arch executives.
The latest: Bob Hugin.
The Celgene CELG CEO perceived remuneration valued at $24.2 million final year, up 15% from 2014, gaining an additional $85.6 million from vested shares and formerly awarded batch options, Celgene pronounced Thursday in the annual proxy.
Celgene markets cancer diagnosis medications Revlimid, Pomalyst and Abraxane, and not long ago invested in Australian branch cell association Mesoblast, giving the association a potentially remunerative event for chartering revenue.
Hugin – who could embrace a golden parachute valued at over $100 million if Celgene is acquired – concluded final year to abstain potentially millions in association supposing taxation sum up payments, Celgene said. Moreover, his 2014 remuneration and equity gains aren’t as large as other biotech CEOs.
Regeneron Pharmaceuticals’ REGN Leonard Schleifer, for example, pulled in scarcely $42 million in salary, reward and batch options final year, gaining an additional $98.4 million sportive formerly awarded batch options. And Gilead Sciences’ GILD John Gilmartin received $187.4 million from vested shares and batch options – on tip of remuneration valued at $18.9 million.
At $3.5 billion, Duggan’s due one of the greatest paydays ever from the buyout of a publicly hold company. Duggan, however, has declined association remuneration given apropos CEO in 2008.
Follow Strauss on Twitter @gstrauss_